Global In Vitro Diagnostics Market Report, First Edition: 2025-2030

Download a sample of the report here.

DeciBio's Global In Vitro Diagnostics (IVD) Market Report is a comprehensive resource, providing a forward-looking view of the global IVD industry, equipping leaders with the insights needed to anticipate shifts, capture opportunities and outpace competitors. IVDs, which have long served as the cornerstone of disease detection and patient monitoring, have a strong influence on every stage of the patient journey. IVD tests enable rapid, accurate assessment of a wide range of conditions, from infectious diseases and cancer to cardiovascular, metabolic, and genetic disorders. Advances in automation, digital pathology, and molecular technologies now allow clinicians to obtain actionable results faster and with higher sensitivity, supporting earlier intervention and more personalized treatment decisions. Ongoing regulatory clearances, rising adoption of point-of-care and at-home testing, and continuous innovation in biomarkers and platforms are expected to drive strong market growth in the near to mid-term. Nevertheless, emerging areas such as multi-omics testing and decentralized precision diagnostics are likely to remain in an early growth phase well beyond the current forecast horizon, offering significant long-term opportunities.

DeciBio’s IVD report assess the IVD landscape, evaluating key technological, clinical, and commercial developments.  Informed by a combination of primary research (25 interviews with diagnostics KOLs), secondary research, proprietary DeciBio databases and tools, and years of consulting experience in the diagnostics and precision medicine markets, this report provides a quantitative and qualitative assessment of the IVD market. Qualitatively, we assess key market players, assays, and technologies, as well as the market drivers, moderators, and trends. Quantitatively, we provide a 5-year (2025 – 2030) market forecast segmented by diagnostic modality (anatomic pathology, clinical chemistry, culture, coagulation, flow cytometry, glucose strip monitoring, immunodiagnostics, mass spectrometry, and molecular diagnostics), therapeutic area (autoimmune / inflammatory, blood screening, cardiology, diabetes, endocrine disorders, general chemistry, hematology, hemostasis, infectious disease, metabolic disease, microbiology, oncology, reproductive testing, transplant, other), geography (U.S., Europe, LATAM, APAC, ROW), and, at a high-level, competitor.

The IVD market is evolving rapidly, and there is much development and strategy that happens outside of the public domain. The assessments and projections made in this report are based only off information that is available in the public domain through October 2025, as well as gathered from primary market research.

The future of IVD is not just about what’s happening today, it’s about what’s coming next. With DeciBio’s independent, data-driven analysis, you will be prepared to anticipate inflection points, identify growth opportunities ahead of competitors, and navigate challenges with confidence.

‍

Key Segmentations Covered:

Diagnostic Modality

• Anatomic Pathology
• Clinical Chemistry
• Coagulation Analysis
• Culture
• Flow Cytometry
• Glucose Strip Monitoring
• Immunoassay
• Mass Spectrometry
• Molecular Diagnostics

Therapeutic Area

• Autoimmune / Inflammatory
• Blood Screening
• Cardiovascular
• Diabetes
• Endocrine
• General Chemistry
• Hematology
• Hemostasis
• Infectious Disease
• Metabolic
• Microbiology
• Oncology
• Reproductive
• Transplant
• Other

Geography

• United States
• Europe
• LATAM
• APAC
• Rest of World

‍

Competitors Profiled:

• Agilent
• Abbott
• BD
• BioMerieux
• Bio-Rad
• Danaher
• Diasorin
• Furjirebio
• Hologic
• QIAGEN
• QuidelOrtho
• Revvity
• Roche
• Siemens Healthineers
• Sysmex
• Thermo Fisher Scientific

‍